# Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial

> **NCT00001146** · PHASE2 · COMPLETED · sponsor: **National Institute of Mental Health (NIMH)** · enrollment: 240 (—)

## Conditions studied

- Bipolar Disorder
- Involutional Depression
- Mood Disorder

## Interventions

- **DRUG:** Ethyl Eicosapentaenoic Acid
- **DRUG:** OmegaBrite

## Key facts

- **NCT ID:** NCT00001146
- **Lead sponsor:** National Institute of Mental Health (NIMH)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-10
- **Primary completion:** —
- **Final completion:** 2002-08
- **Target enrollment:** 240 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001146, "Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00001146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*